Spironolactone
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
- Spironolactone
- Spironolactone: From Aldosterone-Antagonist Diuretic Therapy to Hypotrichosis Simplex of the Scalp
Spironolactone: From Aldosterone-Antagonist Diuretic Therapy to Hypotrichosis Simplex of the Scalp
One-Sentence Summary
Spironolactone is a well-established aldosterone receptor antagonist (potassium-sparing diuretic) used internationally for edema, hypertension, and heart failure. The TxGNN model predicts it may be effective for hypotrichosis simplex of the scalp, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure model output with no external corroboration.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not present in current regulatory dataset (drug is not marketed here); internationally known as an aldosterone antagonist for edema, hypertension, and heart failure |
| Predicted New Indication | Hypotrichosis simplex of the scalp |
| TxGNN Prediction Score | 99.26% |
| Evidence Level | L5 (model prediction only, no supporting studies) |
| India Market Status | Not Marketed |
| Number of Registrations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available from this evidence pack (flagged as a High-severity data gap). Based on known pharmacology, Spironolactone is an aldosterone receptor antagonist with additional antiandrogenic activity, and is used off-label for androgenetic alopecia by blocking the androgen receptor and reducing DHT activity. This is a legitimate, mechanistically grounded repurposing precedent.
However, the disease predicted here — hypotrichosis simplex of the scalp — is a different entity: an autosomal dominant congenital hair-loss disorder most commonly linked to APCDD1 mutations and dysregulation of the Wnt signaling pathway, not androgen-driven miniaturization. There is no known biochemical pathway connecting aldosterone/androgen-receptor blockade to Wnt-pathway–mediated congenital hypotrichosis.
The most likely explanation is that TxGNN’s prediction is driven by phenotypic surface similarity (“hair thinning/loss” as a shared symptom node) rather than a true shared molecular mechanism — a known limitation of knowledge-graph embedding models when a drug already has strong ties to superficially similar phenotypes (in this case, androgenetic alopecia). A second, lower-confidence candidate from the same evidence pack — congenital hypotrichosis milia — shows the identical pattern: a rare genetic hair-and-skin disorder with no plausible link to Spironolactone’s known pharmacology, reinforcing that this is likely a graph-topology artifact rather than a genuine repurposing signal.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
India Market Information
Spironolactone is currently not marketed under this regulatory dataset (0 registrations, 0 licenses on file), so no authorization table can be produced.
Safety Considerations
- Drug Interactions: 272 known interactions on record (DDInter). Notable examples:
- Major: Loperamide
- Moderate: Hydrocortisone, Metformin, Bupropion, Triamcinolone, Morphine, Dexamethasone, Betamethasone, Bisacodyl, Budesonide, Castor oil, Dronabinol, Exenatide, and SGLT2 inhibitors (Canagliflozin, Dapagliflozin, Empagliflozin, Ertugliflozin)
- Minor: Doxycycline, Acetylsalicylic acid, Fidaxomicin
Label-level key warnings and contraindications are not yet available for this drug (blocking data gap — see below); please refer to the official package insert once obtained.
Conclusion and Next Steps
Decision: Hold
Rationale: Despite a high TxGNN similarity score, the mechanistic basis is weak (androgen/aldosterone pathway vs. a Wnt-pathway congenital genetic disorder), there is zero clinical trial or literature support, and the drug is not currently marketed in this jurisdiction. This is an L5, model-only signal that does not meet the bar for further evaluation.
To proceed, the following is needed:
- TFDA (or equivalent local regulator) package insert data — warnings and contraindications (blocking gap, DG001)
- Confirmed mechanism of action via DrugBank API (DG002)
- Any preclinical or genetic evidence linking androgen/mineralocorticoid receptor modulation to Wnt-pathway hair follicle biology
- At minimum, case-level or preclinical evidence specific to hypotrichosis simplex of the scalp before this candidate can move beyond Hold
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.